Molecular mechanism of the schedule-dependent synergistic interaction in EGFR-mutant non-small cell lung cancer cell lines treated with paclitaxel and gefitinib

被引：0
|
作者：
Hua Cheng
She-Juan An
Song Dong
Yi-Fang Zhang
Xu-Chao Zhang
Zhi-Hong Chen
Yi-Long Jian-Su
机构：
[1] Guangdong Lung Cancer Institute; Medical Research Center of Guangdong General Hospital & Guangdong Academy of Medical Sciences,
[2] Thoracic oncology,undefined
[3] the fifth affiliated hospital of Sun Yat-Sen university,undefined
来源：
Journal of Hematology & Oncology | / 4卷
关键词：
Paclitaxel; Gefitinib; Erlotinib; H1650 Cell; Combination Index;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Predictors of response in EGFR-mutant metastatic non-small cell lung cancer patients treated with tyrosine kinase inhibitors
    Dogan, Izzet
    Khanmammadov, Nijat
    Yildiz, Anil
    Ahmed, Melin Aydan
    Vatansever, Sezai
    Saip, Pinar
    Aydiner, Adnan
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2023, 19 (07) : 1945 - 1949
  • [32] Economic analysis of osimertinib in previously untreated EGFR-mutant advanced non-small cell lung cancer in Canada
    Ezeife, Doreen A.
    Kirk, Veronica
    Chew, Derek S.
    Nixon, Nancy A.
    Lee, Roy
    Le, Lisa W.
    Chan, Kelvin K. -W.
    Leighl, Natasha B.
    LUNG CANCER, 2018, 125 : 1 - 7
  • [33] Neoadjuvant Afatinib for stage III EGFR-mutant non-small cell lung cancer: a phase II study
    Bian, Dongliang
    Sun, Liangdong
    Hu, Junjie
    Duan, Liang
    Xia, Haoran
    Zhu, Xinsheng
    Sun, Fenghuan
    Zhang, Lele
    Yu, Huansha
    Xiong, Yicheng
    Huang, Zhida
    Zhao, Deping
    Song, Nan
    Yang, Jie
    Bao, Xiao
    Wu, Wei
    Huang, Jie
    He, Wenxin
    Zhu, Yuming
    Jiang, Gening
    Zhang, Peng
    NATURE COMMUNICATIONS, 2023, 14 (01)
  • [34] The synergistic effect of EGFR tyrosine kinase inhibitor gefitinib in combination with aromatase inhibitor anastrozole in non-small cell lung cancer cell lines
    Shen, Lan
    Li, Ziming
    Shen, Shengping
    Niu, Xiaomin
    Yu, Yongfeng
    Li, Zonghai
    Liao, Meilin
    Chen, Zhiwei
    Lu, Shun
    LUNG CANCER, 2012, 78 (03) : 193 - 200
  • [35] Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines
    La Monica, Silvia
    Galetti, Maricla
    Alfieri, Roberta R.
    Cavazzoni, Andrea
    Ardizzoni, Andrea
    Tiseo, Marcello
    Capelletti, Marzia
    Goldoni, Matteo
    Tagliaferri, Sara
    Mutti, Antonio
    Fumarola, Claudia
    Bonelli, Mara
    Generali, Daniele
    Petronini, Pier Giorgio
    BIOCHEMICAL PHARMACOLOGY, 2009, 78 (05) : 460 - 468
  • [36] Efficacy of gefitinib at reduced dose in EGFR mutant non-small cell lung carcinoma
    Kwok, Wang Chun
    Ho, James Chung Man
    Tam, Terence Chi Chun
    Lui, Macy Mei Sze
    Ip, Mary Sau Man
    Lam, David Chi Leung
    ANTI-CANCER DRUGS, 2019, 30 (10) : 1048 - 1051
  • [37] Recurrence patterns of advanced non-small cell lung cancer treated with gefitinib
    Chen Min-jiang
    Zhong Wei
    Zhang Li
    Zhao Jing
    Li Long-yun
    Wang Meng-zhao
    CHINESE MEDICAL JOURNAL, 2013, 126 (12) : 2235 - 2241
  • [38] Treatment choice in EGFR-mutant non-small-cell lung cancer
    Brueckl, Wolfgang M.
    LANCET ONCOLOGY, 2017, 18 (11) : 1425 - 1426
  • [39] Gefitinib therapy for non-small cell lung cancer
    Birnbaum A.
    Ready N.
    Current Treatment Options in Oncology, 2005, 6 (1) : 75 - 81
  • [40] Ad(aura): a fresh breeze for patients with resected EGFR-mutant non-small cell lung cancer
    Conci, Nicole
    De Giglio, Andrea
    Sperandi, Francesca
    Melotti, Barbara
    Gelsomino, Francesco
    CHINESE CLINICAL ONCOLOGY, 2024, 13 (02)
12345